CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- LAPIX Therapeutics, Inc. (“LAPIX”), a clinical-stage biopharmaceutical company focused on developing novel, orally bioavailable immune system restoration therapies for autoimmune diseases based on agonism of TIM (T cell/transmembrane, immunoglobulin, and mucin receptor), today announced the dosing of first subject with its investigational medicine, LPX-TI641, in its Phase 1b clinical trial (NCT06628206). The Phase 1b trial is a randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and pharmacokinetics in individuals with moderate-to-severe Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA). The Phase 1b study has plans to enroll up to 50 subjects, with topline results anticipated in early 3Q2025.

Go here to read the rest:
LAPIX Therapeutics Doses First Patient-In Phase 1b Clinical Trial of LPX-TI641 for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)